Cytovax is developing new, effective weapons in the fight against infectious diseases. Cytovax's products act through a mechanism that is different from that of current anti-infectives, such as antibiotics, which are designed to kill bacteria directly. The company's proprietary "Anti-Adhesin Technology" prevents infection by blocking the adhesion of pathogens onto human mucosal cells, thus preventing the onset of the infection process, and, accordingly, the antibiotic resistance of the pathogen has no impact on the effectiveness of these anti-adhesin products. Peptide vaccines and monoclonal antibody therapeutics are being developed using this innovative technology to prevent and treat a wide range of pathogens, including Pseudomonas aeruginosa, Streptococcus pneumoniae and other infectious agents that initiate infection in a similar manner. Cytovax's technology has the potential to be a key weapon in the fight against antibiotic-resistant bacteria.

Cytovax's lead product, Cytovaxine™, a consensus sequence peptide, will be used to prevent the intitiation of Pseudomonas aeruginosa infection process through vaccination. Pseudomonas aeruginosa is amoung the leading causes of hospital-acquired pneumonia, and in 35% to 45% of infections, the organism is resistant to the best drug that would normally be chosen to treat that organism.

As an alternative to vaccination and for situations where the patient is at immediate risk of infection, Cytovax plans to use its proprietary technology to treat diseases through the introduction of monoclonal antibodies. Cytovax is currently in the pre-clinical phase for a monclonal antibody therapeutic for Pseudomonas aeruginosa, and has demonstrated the effectiveness of the therapeutic in mice subjected to a lethal dose of Pseudomonas aeruginosa.

Cytovax anticipates that it will choose Streptococcus pneumoniae as its second target product, and may seek to develop both a vaccine and monoclonal antibody therapeutic to prevent and treat this disease.

Sourdough fermentation, a traditional biotechnology for making leavened baked goods, was almost completely replaced by the use of baker's yeast and chemical leavening agents in the last century. Recen...

Currently, sperm reproductive biotechnologies such as sex sorting and cryopreservation are undoubtedly valuable tools for improving the economic and biological efficiency of red deer production system...

I have been involved with the current interest in de-extinction since early 2012, nearly its beginning. I have given a lot of thought to the potential risks and benefits of de-extinction. But only rec...

Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung dep...

According to the expressivist argument the choice to use biotechnologies to prevent the birth of individuals with specific disabilities is an expression of disvalue for existing people with this disab...

Clinical Trials
[0 Results]

Cytovax Biotechnologies Inc. is a biotechnology company focused on the development of novel approaches for the prevention and treatment of infectious diseases.Cytovax is developing new, effective weap...

NEXGEN Biotechnologies, Inc. is the specialized 2nd Generation Plant Biotechnology company begun firstly in Korea.NEXGEN Biotechnologies, Inc., established in November 1999, is the venture biotechnolo...

More Information about "Cytovax Biotechnologies Incorporated" on BioPortfolio

Biotechnology - Biotech"using living things to create products or to do tasks for humans"
About Biotechnology - Biotech
Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...